Evidence map›Paper›PMID 29200434›Full record

ArticlePloS one2017

Iron-induced oligomerization of human FXN81-210 and bacterial CyaY frataxin and the effect of iron chelators.

Eva-Christina Ahlgren, Mostafa Fekry, Mathias Wiemann, Christopher A Söderberg, Katja Bernfur, Olex Gakh, Morten Rasmussen, Peter Højrup, Cecilia Emanuelsson, Grazia Isaya and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Effects of FeInternational journal of molecular sciences · 2020
    Article
  6. Review
  7. Review
  8. Impact ofInternational journal of molecular sciences · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Eva-Christina AhlgrenCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Mostafa FekryCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Mathias WiemannCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Christopher A SöderbergCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Katja BernfurCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Olex GakhDepartments of Pediatric and Adolescent Medicine and Biochemistry and Molecular Biology, Mayo Clinic, College of Medicine, Rochester, Minnesota, United States of America.
Morten RasmussenDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Peter HøjrupDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Cecilia EmanuelssonCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.
Grazia IsayaDepartments of Pediatric and Adolescent Medicine and Biochemistry and Molecular Biology, Mayo Clinic, College of Medicine, Rochester, Minnesota, United States of America.
Salam Al-KaradaghiCenter for Molecular Protein Science, Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-8608-0635
Lund University · SEMayo Clinic · USUniversity of Southern Denmark · DKCairo University · EG

Funding

NEW DETERMINANTS OF MTDNA INTEGRITY IN YEAST AND HEARTR01AG015709 · NIA · YALE UNIVERSITY · PI ISAYA, GRAZIA · 1997 to 2015
$4.0M
NIA NIH HHS R01 AG015709
6 · The paper itself

Abstract

Patients suffering from the progressive neurodegenerative disease Friedreich's ataxia have reduced expression levels of the protein frataxin. Three major isoforms of human frataxin have been identified, FXN42-210, FXN56-210 and FXN81-210, of which FXN81-210 is considered to be the mature form. Both long forms, FXN42-210 and FXN56-210, have been shown to spontaneously form oligomeric particles stabilized by the extended N-terminal sequence. The short variant FXN81-210, on other hand, has only been observed in the monomeric state. However, a highly homologous E. coli frataxin CyaY, which also lacks an N-terminal extension, has been shown to oligomerize in the presence of iron. To explore the mechanisms of stabilization of short variant frataxin oligomers we compare here the effect of iron on the oligomerization of CyaY and FXN81-210. Using dynamic light scattering, small-angle X-ray scattering, electron microscopy (EM) and cross linking mass spectrometry (MS), we show that at aerobic conditions in the presence of iron both FXN81-210 and CyaY form oligomers. However, while CyaY oligomers are stable over time, FXN81-210 oligomers are unstable and dissociate into monomers after about 24 h. EM and MS studies suggest that within the oligomers FXN81-210 and CyaY monomers are packed in a head-to-tail fashion in ring-shaped structures with potential iron-binding sites located at the interface between monomers. The higher stability of CyaY oligomers can be explained by a higher number of acidic residues at the interface between monomers, which may result in a more stable iron binding. We also show that CyaY oligomers may be dissociated by ferric iron chelators deferiprone and DFO, as well as by the ferrous iron chelator BIPY. Surprisingly, deferiprone and DFO stimulate FXN81-210 oligomerization, while BIPY does not show any effect on oligomerization in this case. The results suggest that FXN81-210 oligomerization is primarily driven by ferric iron, while both ferric and ferrous iron participate in CyaY oligomer stabilization. Analysis of the amino acid sequences of bacterial and eukaryotic frataxins suggests that variations in the position of the acidic residues in helix 1, β-strand 1 and the loop between them may control the mode of frataxin oligomerization.

Indexed as

Protein MultimerizationBinding SitesCross-Linking ReagentsDynamic Light ScatteringEscherichia coli ProteinsFrataxinFriedreich AtaxiaHumansIronIron-Binding ProteinsIron Chelating AgentsMass SpectrometryMicroscopy, ElectronModels, MolecularProtein IsoformsRecombinant ProteinsCross-Linking ReagentsEscherichia coli ProteinsFrataxinIronIron-Binding ProteinsIron Chelating AgentsProtein IsoformsRecombinant Proteins

Identifiers

PMID29200434
PMCPMC5714350
OpenAlexW2771342277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.